» Authors » Matthias Roesslein

Matthias Roesslein

Explore the profile of Matthias Roesslein including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 226
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Petersen E, Barrios A, Henry T, Johnson M, Koelmans A, Montoro Bustos A, et al.
Environ Sci Technol . 2022 Oct; 56(22):15192-15206. PMID: 36240263
To fully understand the potential ecological and human health risks from nanoplastics and microplastics (NMPs) in the environment, it is critical to make accurate measurements. Similar to past research on...
2.
Halamoda-Kenzaoui B, Geertsma R, Pouw J, Prina-Mello A, Carrer M, Roesslein M, et al.
Drug Deliv Transl Res . 2022 Jun; 12(9):2145-2156. PMID: 35691982
The identification of regulatory challenges for nanotechnology-enabled health products, followed by discussions with the involved stakeholders, is the first step towards a strategic planning of how such challenges can be...
3.
Minelli C, Wywijas M, Bartczak D, Cuello-Nunez S, Infante H, Deumer J, et al.
Nanoscale . 2022 Mar; 14(12):4690-4704. PMID: 35262538
We describe the outcome of a large international interlaboratory study of the measurement of particle number concentration of colloidal nanoparticles, project 10 of the technical working area 34, "Nanoparticle Populations"...
4.
Petersen E, Nguyen A, Brown J, Elliott J, Clippinger A, Gordon J, et al.
ALTEX . 2021 Feb; 38(2):365-376. PMID: 33637998
The use of in vitro assays to inform decision-making requires robust and reproducible results across studies, laboratories, and time. Experiments using positive control materials are an integral component of an...
5.
Nelson B, Minelli C, Doak S, Roesslein M
Annu Rev Anal Chem (Palo Alto Calif) . 2020 Feb; 13(1):431-452. PMID: 32084321
Development and application of nanotechnology-enabled medical products, including drugs, devices, and in vitro diagnostics, are rapidly expanding in the global marketplace. In this review, the focus is on providing the...
6.
Petersen E, Hirsch C, Elliott J, Krug H, Aengenheister L, Arif A, et al.
Chem Res Toxicol . 2019 Sep; 33(5):1039-1054. PMID: 31507156
One of the challenges in using data to understand the potential risks of engineered nanomaterials (ENMs) is that results often differ or are even contradictory among studies. While it is...
7.
Cassano J, Roesslein M, Kaufmann R, Luethi T, Schicht O, Wick P, et al.
ALTEX . 2019 Sep; 1(37):95-109. PMID: 31473765
The routine use of single cell gel electrophoresis assay in medical diagnostics and biomonitoring is prevented by its high variability. Several factors have been identified and can be grouped into...
8.
Halamoda-Kenzaoui B, Baconnier S, Bastogne T, Bazile D, Boisseau P, Borchard G, et al.
Regul Toxicol Pharmacol . 2019 May; 106:187-196. PMID: 31051191
An early dialogue between nanomedicine developers and regulatory authorities are of utmost importance to anticipate quality and safety requirements for these innovative health products. In order to stimulate interactions between...
9.
Bohmer N, Rippl A, May S, Walter A, Heo M, Kwak M, et al.
Colloids Surf B Biointerfaces . 2018 Sep; 172:635-645. PMID: 30243217
Nanotechnology is regarded as the enabling technology of the 21st century. However, only a relatively small number of nano-enabled medical and healthcare products finally made their way to the market....
10.
Kaiser J, Roesslein M, Diener L, Wichser A, Nowack B, Wick P
J Nanobiotechnology . 2017 Jan; 15(1):5. PMID: 28061858
Background: Nanosilver shows great promise for use in industrial, consumer or medical products because of its antimicrobial properties. However, the underlying mechanisms of the effects of silver nanoparticles on human...